Resmed Announces Agreement to Sell MatrixCare Business

Rhea-AI Summary

Resmed (NYSE:RMD) entered a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a healthcare-focused private equity firm. The deal aligns with Resmed’s 2030 strategy to prioritize high-growth sleep, breathing and connected home-based care and to reallocate capital toward innovation and operational scale.

The sale covers MatrixCare and related brands, including Healthcare First and Citus, but excludes Brightree and MEDIFOX DAN. Closing is targeted for the first quarter of Resmed’s fiscal 2027, subject to regulatory approvals and customary conditions. MatrixCare will operate within Resmed until completion.

Positive

• Divestiture supports focus on high-growth sleep and connected care markets
• Transaction expected to enhance capital allocation toward innovation and scale
• Non-core MatrixCare business and related software carved out while retaining Brightree and MEDIFOX DAN
• Definitive agreement provides clearer strategic positioning for long-term value creation

Negative

• Resmed exits MatrixCare segment serving over 15,000 long-term and post-acute care providers
• Transaction closing depends on regulatory approvals and customary conditions, creating timing uncertainty

News Market Reaction – RMD

-6.33%

8 alerts

-6.33% Session close to close

-2.3% Trough in 6 hr 23 min

$31.68B Market Cap

0.8x Rel. Volume

In the Jul 8 session, RMD declined 6.33%, reflecting a notable negative market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.3% in the session following this news. A sharp selloff could indicate concern abo...

Analysis

The stock moved -6.3% in the session following this news. A sharp selloff could indicate concern about losing MatrixCare’s software contribution or about execution on capital redeployment. Prior strategic updates have sometimes sold off, and recent insider net selling may add to perceived governance and alignment risks.

Key Figures

Strategy horizon: 2030 Provider count: more than 15,000 providers Expected closing timing: first quarter fiscal 2027 +5 more

8 metrics

Strategy horizon 2030 Resmed’s long-term strategic plan reference year

Provider count more than 15,000 providers MatrixCare software customer base

Expected closing timing first quarter fiscal 2027 Anticipated closing of MatrixCare divestiture

Financial impact update timing fourth quarter fiscal 2026 Planned disclosure of transaction’s financial impact

Pre-headline price move 4.18% RMD price change over prior 24 hours

52-week high discount -25.21% RMD price vs 52-week high before announcement

52-week low premium 21.9% RMD price vs 52-week low before announcement

Short interest days to cover 9.02 days Based on reported short interest and average volume

Historical Context

5 past events · Latest: Jun 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 30	earnings scheduling	Neutral	+3.2%	Announcement of date and time for Q4 fiscal 2026 earnings release.
Jun 01	sleep portfolio acquisition	Positive	-1.9%	Completion of Noctrix Health acquisition to expand clinical sleep health portfolio.
May 19	conference participation	Neutral	+1.2%	CEO and CFO participation in William Blair Growth Stock Conference webcast.
May 19	consumer partnership	Positive	+1.7%	Partnership with Oura to expand access to sleep health education and care.
Apr 30	leadership change	Neutral	-4.1%	CFO retirement announcement and appointment of successor with outlook reiterated.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent headlines have drawn mixed reactions, with acquisitions and leadership changes sometimes met with selling despite generally strategic positioning.

Key Terms

definitive agreement, form 8-k, regulatory approvals, customary closing conditions

4 terms

definitive agreement regulatory

"today announced it has entered into a definitive agreement to sell its MatrixCare"

A definitive agreement is a formal, legally binding document that outlines the final terms and conditions of a deal or transaction, such as a sale or partnership. It acts like a detailed contract that confirms all parties have agreed on the key details, making the deal official. For investors, it signals that the agreement is settled and moving toward completion, providing clarity and security about the transaction.

form 8-k regulatory

"information regarding this transaction through a Form 8-K furnished with the U.S."

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

regulatory approvals regulatory

"expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals"

Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

customary closing conditions regulatory

"fiscal year 2027, subject to required regulatory approvals and customary closing conditions."

"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Sharpens Resmed’s focus on high-growth sleep and connected care markets

SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care.

This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem.

MatrixCare provides software solutions to more than 15,000 providers and supports skilled nursing, senior living and long-term care, life planning communities and home health and hospice care.

“Today’s announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth,” said Mick Farrell, Chairman and CEO of Resmed. “By focusing on areas where we see the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes and create value for our stakeholders. We are confident MatrixCare and its affiliated businesses will continue to support team members and drive growth under new ownership with a dedicated focus on the long-term care market.”

“Frazier has spent several years evaluating the post-acute care technology sector and believes MatrixCare has established itself as a leading platform serving skilled nursing, senior living and home health and hospice providers,” said Ryan Lucero, General Partner at Frazier Healthcare Partners. “We are thrilled to partner with the MatrixCare team and plan to invest aggressively in product innovation to help providers deliver better outcomes as the post-acute care landscape continues to evolve.” 

The transaction includes MatrixCare and related software offerings historically sold under the MatrixCare brand, including Healthcare First, Citus and home health and hospice solutions (collectively defined as the “MatrixCare business”). It excludes Resmed’s other software businesses, Brightree in the U.S. and MEDIFOX DAN in Germany.

The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Until closing, MatrixCare will continue to operate as part of Resmed, with no changes to customer service or support.

Resmed is providing additional information regarding this transaction through a Form 8-K furnished with the U.S. Securities and Exchange Commission (SEC). Supplementary materials related to this press release are available on Resmed’s Investor Relations website at investor.resmed.com.

Resmed will provide further updates regarding the financial impact of the transaction in its regulatory filings for the fourth quarter of its fiscal year 2026, consistent with regulatory requirements.

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.

About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier is headquartered in Seattle, WA, with an office in New York City, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier, visit www.frazierhealthcare.com/home.

For Media
Brad Lotterman Brad.Lotterman@resmed.com
news@resmed.com

For Investors
Salli Schwartz Salli.Schwartz@resmed.com
investorrelations@resmed.com

FAQ

What did Resmed (NYSE:RMD) announce about its MatrixCare business on July 7, 2026?

Resmed announced a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners. According to Resmed, the move aligns with its 2030 strategy, sharpening focus on sleep health, breathing health and connected home-based care while reallocating capital and resources.

Which assets are included in Resmed’s sale of the MatrixCare business to Frazier Healthcare Partners?

The transaction includes MatrixCare and related software historically sold under the MatrixCare brand. According to Resmed, this covers Healthcare First, Citus and home health and hospice solutions, while excluding its other software businesses Brightree in the U.S. and MEDIFOX DAN in Germany.

When is Resmed’s sale of MatrixCare to Frazier Healthcare Partners expected to close?

The transaction is expected to close in the first quarter of Resmed’s fiscal year 2027. According to Resmed, completion is subject to required regulatory approvals and customary closing conditions, and MatrixCare will continue operating within Resmed until the deal closes.

How does selling MatrixCare fit into Resmed’s 2030 strategy and focus on sleep and connected care?

The sale supports a sharper focus on high-growth, scalable sleep and connected home-based healthcare opportunities. According to Resmed, divesting MatrixCare allows capital and resources to be reallocated toward innovation, operational scale and long-term value creation in its core connected, home-based care ecosystem.

Will Resmed’s other software platforms Brightree and MEDIFOX DAN be affected by the MatrixCare sale?

Brightree and MEDIFOX DAN are excluded from the MatrixCare transaction and remain with Resmed. According to Resmed, only software historically sold under the MatrixCare brand, including Healthcare First and Citus, is part of the divestiture to Frazier Healthcare Partners.

What happens to MatrixCare customers and services before Resmed’s sale to Frazier closes?

MatrixCare will continue operating as part of Resmed until the transaction closes. According to Resmed, there will be no changes to customer service or support for MatrixCare clients during this interim period while regulatory approvals and closing conditions are satisfied.